{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:48:20Z","timestamp":1778881700160,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41409-018-0170-0","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T14:11:38Z","timestamp":1525183898000},"page":"1445-1449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma"],"prefix":"10.1038","volume":"53","author":[{"given":"Nishant","family":"Tageja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Panch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan F.","family":"Leitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Sportes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"170_CR1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V90.1.340.340_340_345","volume":"90","author":"NE Kay","year":"1997","unstructured":"Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 1997;90:340\u20135.","journal-title":"Blood"},{"key":"170_CR2","first-page":"1034","volume":"11","author":"M Zandecki","year":"1997","unstructured":"Zandecki M, Bernardi F, Genevieve F, La\u00ef JL, Preudhomme C, Flactif M, et al. Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes. Leukemia. 1997;11:1034\u20139.","journal-title":"Leukemia"},{"key":"170_CR3","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","volume":"19","author":"AK Stewart","year":"2001","unstructured":"Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771\u20139.","journal-title":"J Clin Oncol"},{"key":"170_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3324\/haematol.10535","volume":"92","author":"JH Bourhis","year":"2007","unstructured":"Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica. 2007;92:1083\u201390.","journal-title":"Haematologica"},{"key":"170_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746\u201354.","journal-title":"JAMA Oncol"},{"key":"170_CR6","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood-2008-03-143677","volume":"112","author":"S Vasu","year":"2008","unstructured":"Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112:2092\u2013100.","journal-title":"Blood"},{"key":"170_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","volume":"38","author":"PR Tembhare","year":"2014","unstructured":"Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38:371\u20136.","journal-title":"Leuk Res"},{"key":"170_CR8","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127:3165\u201374.","journal-title":"Blood"},{"key":"170_CR9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"170_CR10","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035\u201342.","journal-title":"Leukemia"},{"key":"170_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bmt.2016.24","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren O, Giralt S. MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients. Bone Marrow Transplant. 2016;51:913\u20134.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0170-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:55Z","timestamp":1684617115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0170-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"22 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Landgren has given scientific talks at meetings supported by unrestricted grants from Amgen, Celgene, Takeda, BMS, Janssen, and Merck; he has served on Independent Data Monitoring Committees (IDMCs) for clinical trials led by Janssen, Takeda, and Merck; also he has served as the Chairman for Medscape Myeloma Program. The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}